Literature DB >> 23872728

Use of mastoid obliteration techniques in cholesteatoma.

Matthew Yung1, Alex Bennett.   

Abstract

PURPOSE OF REVIEW: To evaluate the choice of techniques, safety and long-term outcome of mastoid obliteration and assess the place of imaging in the postoperative monitoring of residual cholesteatoma. RECENT
FINDINGS: All recent reports on mastoid obliteration for the management of cholesteatoama were favourable. Long-term follow-up reports did not show problems arising from hidden cholesteatoma, even for the paediatric population. Non-EPI DW MR imaging has shown great promise in detecting residual cholesteatoma in obliterated cavities.
SUMMARY: Canal wall down technique with primary mastoid obliteration for cholesteatoma has low recurrent and residual cholesteatoma rates. Most ears remained dry and waterproof on long-term follow-up.

Entities:  

Mesh:

Year:  2013        PMID: 23872728     DOI: 10.1097/MOO.0b013e3283646521

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  11 in total

Review 1.  [Obliteration of mastoid cavities: 30 years of experience with recommendations for surgical strategy].

Authors:  G Schimanski; E Schimanski
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

2.  Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.

Authors:  Joris Vos; Pieter de Vey Mestdagh; David Colnot; Pepijn Borggreven; Claudia Orelio; Jasper Quak
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-27       Impact factor: 2.503

3.  Mastoid obliteration with hydroxyapatite vs. bone pâté in mastoidectomy surgery performed on patients with cholesteatoma and chronic suppurative otitis media: a retrospective analysis.

Authors:  Jantine J Lindeboom; P M W van Kempen; J Buwalda; B O Westerlaken; D A van Zuijlen; S J H Bom; F B van der Beek
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-29       Impact factor: 3.236

4.  The Hannover Coupler V2: Audiological outcomes of a round window coupler for the Vibrant Soundbridge.

Authors:  Nicole Knölke; Dawid Murawski; Nina Wardenga; Susan Busch; Hannes Maier; Thomas Lenarz
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-05-28

5.  Canal wall reconstruction in cholesteatoma surgeries: rate of residual.

Authors:  A Roux; D Bakhos; E Lescanne; J-P Cottier; A Robier
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-17       Impact factor: 2.503

6.  Post-operative healing and long-term stability after mastoid cavity reconstruction using the middle temporal artery and inferior musculoperiosteal flaps.

Authors:  Arthur Dexian Tan; Jia Hui Ng; David Yong-Ming Low; Heng Wai Yuen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-15       Impact factor: 2.503

7.  Implantation of the Bonebridge BCI 602 after Mastoid Obliteration with S53P4 Bioactive Glass: A Safe Method of Treating Difficult Anatomical Conditions-Preliminary Results.

Authors:  Bartłomiej Król; Katarzyna Beata Cywka; Magdalena Beata Skarżyńska; Piotr Henryk Skarżyński
Journal:  Life (Basel)       Date:  2021-04-22

Review 8.  Updates and knowledge gaps in cholesteatoma research.

Authors:  Chin-Lung Kuo; An-Suey Shiao; Matthew Yung; Masafumi Sakagami; Holger Sudhoff; Chih-Hung Wang; Chyong-Hsin Hsu; Chiang-Feng Lien
Journal:  Biomed Res Int       Date:  2015-03-18       Impact factor: 3.411

Review 9.  Mastoid Obliteration with Autologous Bone in Mastoidectomy Canal Wall Down Surgery: a Literature Overview.

Authors:  Ricardo Dourado Alves; Francisco Cabral Junior; Anna Carolina de Oliveira Fonseca; Ricardo Ferreira Bento
Journal:  Int Arch Otorhinolaryngol       Date:  2015-08-24

10.  Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.

Authors:  Tommaso Cacco; Stefano Africano; Gilda Gaglio; Luca Carmisciano; Enrico Piccirillo; Eolo Castello; Giorgio Peretti
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-22       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.